> 首页 > 产品 > 一抗 > 其他 > Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab)

Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab)

Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) is 100.00%, determined by SEC-HPLC.
Gefurulimab bound to HSA protein, and then rebounded to secondary antibodies (Anti-human-κ+λ-HRP) , and read OD450. As shown in fig, Gefurulimab bound to HSA-Fc , and the EC50 was 0.006 nM.
Co-incubation of Gefurulimab with complement protein, then with the addition of Rituximab and Raji cells and incubated for 4 hours. CTG was used to detect the luciferase signal. As shown in fig, Gefurulimab can block rituximab-induced CDC killing, and the IC50 was 18.090 nM.
The detected molecular weight of Anti-C5 & Serum Albumin Reference Antibody (Gefurulimab) is 28.99 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P01031 & P02768
Reactivity	Human
Clonality	Bispecific
Isotype	VHH-VHH

Additional Information
Target/Specificity	Complement C5,Serum Albumin / SA / HSA
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.